These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19087221)

  • 1. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.
    Foley JH; Nesheim ME
    J Thromb Haemost; 2009 Mar; 7(3):453-9. PubMed ID: 19087221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO
    J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
    Foley JH; Nesheim ME; Rivard GE; Brummel-Ziedins KE
    Haemophilia; 2012 May; 18(3):e316-22. PubMed ID: 21933309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
    Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
    J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time.
    Urano T; Sano Y; Suzuki Y; Okada M; Sano H; Honkura N; Morooka N; Doi M; Suzuki Y
    Res Pract Thromb Haemost; 2024 May; 8(4):102463. PubMed ID: 39026660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.
    Semeraro F; Mancuso ME; Ammollo CT; Dirienzo L; Vitulli A; Santagostino E; Tripodi A; Colucci M
    J Thromb Haemost; 2020 Feb; 18(2):381-389. PubMed ID: 31571361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
    Broze GJ; Higuchi DA
    Blood; 1996 Nov; 88(10):3815-23. PubMed ID: 8916945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
    Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
    Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
    Ammollo CT; Semeraro F; Vitulli A; Dirienzo L; Mezzasoma AM; Semeraro N; Gresele P; Colucci M
    Haemophilia; 2020 Jul; 26(4):e151-e160. PubMed ID: 32325538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
    van Moorsel MVA; Poolen GC; Koekman CA; Verhoef S; de Maat S; Barendrecht A; van Kleef ND; Meijers JCM; Schiffelers RM; Maas C; Urbanus RT
    J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients.
    Mikovic D; Woodhams BJ; Holmström M; Elezovic I; Antovic A; Mobarrez F; Elfvinge P; Antovic JP
    Int J Lab Hematol; 2012 Feb; 34(1):35-40. PubMed ID: 21707936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
    Higuchi T; Nakamura T; Kakutani H; Ishii H
    Biol Pharm Bull; 2009 Feb; 32(2):179-85. PubMed ID: 19182372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
    Bajzar L; Nesheim M; Morser J; Tracy PB
    J Biol Chem; 1998 Jan; 273(5):2792-8. PubMed ID: 9446587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
    Plug T; Marquart JA; Marx PF; Meijers JC
    J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.
    Wyseure T; Cooke EJ; Declerck PJ; Behrendt N; Meijers JCM; von Drygalski A; Mosnier LO
    Blood; 2018 Oct; 132(15):1593-1603. PubMed ID: 30026184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
    Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
    Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
    Schneider M; Nesheim M
    J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L; Nesheim ME; Tracy PB
    Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
    Boffa MB; Wang W; Bajzar L; Nesheim ME
    J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.